论文部分内容阅读
Sumatriptan是一种新的选择性5-HT_1受体激动剂。本文采用双盲、安慰剂对照试验评价了皮下注射本品治疗偏头痛的疗效和安全性。 639例偏头痛病人在行基础临床评价后,随机、双盲皮下注射安慰剂(106例)、本品6mg(423例)和本品8 mg(110例)。给药1小时后头痛未完全消失者再行第二次双盲皮下给药:安慰剂组和8 mg组均给予安慰剂,而6 mg组则给予本品6mg或安慰剂。首
Sumatriptan is a new and selective 5-HT_1 receptor agonist. This article uses a double-blind, placebo-controlled trial to evaluate the efficacy and safety of subcutaneous injections of this product in the treatment of migraine. Six hundred and sixty-three migraineurs received a randomized, double-blind subcutaneous placebo (106 patients), 6 mg (423 patients), and 8 mg (110 patients) of this product after a baseline clinical evaluation. One hour after the administration, the headache was not completely disappeared and then the second double-blind subcutaneous administration: placebo and 8 mg group were given placebo, while the 6 mg group was given this product 6 mg or placebo. first